Teva Pharma (TEVA) Reports In-Line Q1 EPS on Light Revs
Teva Pharmaceutical Industries Limited (NASDAQ: TEVA) reported Q1 EPS of $1.04, in-line with the analyst estimate of $1.04. Revenue for the quarter came in at $4.08 billion versus the consensus estimate of $4.25 billion.